Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 4, 1999, Pages 199-205

  Kiriyama, Akiko ^a   Nishiura, Tomoyuki ^a   Yamaji, Hirokazu ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

HIV 1 protease inhibitor; KNI 272; Michaelis Menten type metabolism; Nonlinear pharmacokinetics; Physiologically based pharmacokinetic model; Rat

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; KYNOSTATIN 272; PROTEINASE INHIBITOR;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; MICHAELIS MENTEN KINETICS; NONHUMAN; RAT;

ANIMALS; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0032864188     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199905)20:4<199::AID-BDD174>3.0.CO;2-4     Document Type: Article

References (32)

1. Mimoto T, Imai J, Kisanuki S, Enomoto H, Hattori N, Akaji K, Kiso, Y. Kynostatine (KNI)-227 and -272, highly potent anti-HIV agents: Conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem Pharm Bull 1992; 40: 2251-2253.
2. Kageyama S, Mimoto T, Murakawa Y, Nomizu M, Ford H Jr, Shirasaka T, Gulnik S, Erickson J, Takada K, Hayashi H, Broder S, Kiso Y, Mitsuya H. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetric HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother 1993; 37: 810-817.
3. Kiriyama A, Mimoto T, Kisanuki S, Kiso Y, Takada K. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations. Biopharm Drug Dispos 1993; 14: 697-707.
4. Kiriyama A, Mimoto T, Kiso Y, Takada K. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations. Biopharm Drug Dispos 1993; 14: 199-207.
5. Sugahara M, Kiriyama A, Hamada Y, Kiso Y, Takada K. Absorption of new HTV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: Effect of solvent. Biopharm Drug Dispos 1995; 16: 269-277.
6. Kiriyama A, Sugahara M, Yoshikawa Y, Kiso Y, Takada K. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs. Biopharm Drug Dispos 1996; 17: 125-134.
7. Kiriyama A, Fujita K, Takemura S, Kuramoto H, Kiso Y, Takada K. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration. Biopharm Drug Dispos 1994; 15: 617-626.
8. Kiriyama A, Nishiura T, Yamaji H, Takada K. Metabolic characterization of a tripeptide HTV-1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother 1999; 43: 549-556.
9. Balani SK, Arison BH, Mathai L, Kauffman LR, Miller RR, Stearns RA, Chen I-W, Lin JH. Metabolites of L-735,524, a potent HTV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23: 266-270.
10. Balani SK, Pitzenberger SM, Schwartz MS, Ramjit HG, Thompson WJ. Metabolism of L-689,502 by rat liver slices to potent HTV-1 protease inhibitors. Drug Metab Dispos 1995; 23: 185-189.
11. Denissen JF, Grabowski BA, Johnson MK, Boyd SA, Uchic JT, Stein H, Cepa S, Hill P. The orally active renin inhibitor A-74273: In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metab Dispos 1994; 22: 880-888.
12. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HTV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-431.
13. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, Surber BW. Metabolism and disposition of the HTV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 1997; 25: 489-501.
14. Balani SK, Pitzenberger SM, Kauffman LR, Arison BH, Ramjit HG, Goldman ME, O'Brien JA, King JD, Hoffman JM, Rooney CS, Theoharides AD. Metabolism of a new HTV-1 reverse transcriptase inhibitor, 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methypridine-2(1H)-one (L-696,229), in rat and liver slices. Drug Metab Dispos 1992; 20: 869-876.
15. Balani SK, Kauffman LR, Arison BH, Olah TV, Goldman ME, Varga SL, O'Brien JA, Ramjit HG, Rooney CS, Hoffman JM, Pitzenberger SM. Metabolism of 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methypridine-2(1H)-one (L-696,229), an HTV-1 reverse transcriptase inhibitor, by rat liver slices and in humans. Drug Metab Dispos 1994; 22: 200-205.
16. Lin JH, Sugiyama Y, Awazu S, Hanano M. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm 1982; 10: 649-661.
17. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
18. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19: 21-50.
19. Kiriyama A, Nishiura T, Ishino M, Yamamoto Y, Ogita I, Kiso Y, Takada K. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor. Biopharm Drug Dispos 1996; 17: 9-51.
20. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical consideration of a 'well-stirred' and a 'parallel tube' model. Influence of hepatic blood, plasma and blood binding and hepatocellular enzyme activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625-653.
21. Lin JH, Sugiyama Y, Awazu S, Hanano M. In vitro and in vivo evaluation of the tissue-to-plasma partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm 1982; 10: 637-647.
22. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
23. Ichimura F, Deguchi Y, Yokogawa K, Yamana T. Physiologically based pharmacokinetics of valproic acid in rabbits. Int J Pharm 1985; 27: 45-60.
24. Nagata O, Murata M, Kato H, Terasaki T, Sato H, Tsuji A. Physiological pharmacokinetics of a new muscle-relaxant, inaperizone, combined with its pharmacological effect on blood flow rate. Drug Metab Dispos 1990; 18: 902-910.
25. Gallo JM, Cheung LL, Kim HJ, Bruckner JV, Gillespie WR. A physiological and system analysis hybrid pharmacokinetic model to characterize carbon tetrachloride blood concentrations following administration in different oral vehicles. J Pharmacokinet Biopharm 1993; 21: 551-574.
26. Varkonyi P, Bruckner JV, Gallo JM. Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations. J Pharm Sci 1995; 84: 381-384.
27. Sugiyama Y. Reconstruction of drug dispositions in vivo from in vitro studies based on physiological pharmacokinetic modeling: From low-molecular weight drugs to polypeptide compounds. Yakugaku Zasshi 1989; 109: 199-231.
28. Pantaleo G, Graziosi G, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-358.
29. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-362.
30. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompsom MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS society-USA. J Am Med Assoc 1996; 276: 146-154.
31. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
32. du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24: 435-440.